RICHT.BDRICHT.BD

RICHT.BD is a research site focused on psychiatry. The company has conducted numerous clinical trials for Reagila, a drug proposed for the treatment of schizophrenia in adult patients, including those with predominant negative symptoms. These trials have enrolled a significant number of patients across various countries. For instance, trial RGH-MD-06 included 765 patients from the USA, India, Romania, Slovakia, and Ukraine, while RGH-MD-16 involved 732 patients from the USA, India, Russia, Ukraine, and Malaysia. Other trials, such as RGH-MD-04, enrolled 617 patients from the USA, Romania, Russia, and Ukraine, and RGH-MD-05 included 446 patients from the USA, Colombia, India, and South Africa. The proposed daily dose range for Reagila is 1.5-6 mg, with an initial dose of 1.5 mg and dose increments of 1.5 to 3 mg, up to a maximum daily dose of 6 mg.